Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019